CS MEDICA A/S Announces FDA authorization for commercialization for Eight Products in the U.S. Market

The authorization marks a significant step in the company's growth journey, resulting in the U.S. market expansion will be moved forward.

CS MEDICA A/S is proud to announce that they obtained the company registration number: Owner Operator Number: 10089433(Medical Devices) & FEI number: 3030062474(Cosmetic), at the U.S. Food and Drug Administration (FDA) and has registered Eight innovative products for sale in the United States. This milestone approval includes a range of VET and cosmetic products and three medical devices designed for over-the-counter pain relief.

The list of approved products is*;

Medical Devices:

• Pain Patch
• Nasal Night Spray
• Wound Gel

Cosmetic:

• Anti-Hair loss serum
• Skin Relief Lotion

Vet products:

• Pain Patch
• Pain & Arthritis Gel
• Wound Gel

Each of these products features Cannabis Sativa L as part of the synergy of the ingredients, reflecting our commitment to harnessing the potentials of cannabis. The [CD1]listing of these products in the FDA database, marks a significant step in our journey, especially considering the U.S. is one of the most developed markets for cannabis-infused products.

The medical devices and cosmetic products will be live on Amazon in January 2024 to advance the company's go-to-market plans for the U.S. territory. New distribution partners are expected to be onboarded during the first quarter of 2024. This strategic move will enable the company to reach a wider audience, ensuring the products are easily accessible to consumers across the United States.

CS MEDICA's CEO, Lone Henriksen, expressed her enthusiasm about this development: "Receiving FDA notification approval for these eight products is not just a triumph for us, but a testament to the research and dedication behind our products. The U.S. market is pivotal in the cannabis sector, but yet a grey market for safety and proof of concept, especially for different functions of the cannabis then traditional ones. Hence, our entry through this approval marks a significant milestone in our global expansion strategy. We are eager to bring our innovative treatments to American consumers and are confident that our presence on the market will be a game-changer in how people experience our products and company.".

For more information about CS MEDICA A/S and our range of treatments, please visit www.cannasen.com.

* https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/textsearch.cfm  – write Cannordic as Company name in the search field.